A clinical trial studying bariatric surgery as a radical treatment for type 2 diabetes has commenced in Europe:
Instead, investigators have found, bariatric surgery, independent of weight loss, alters metabolic factors such as the hunger-regulating peptide hormone ghrelin (as a result of decreased gastric mass). In addition, bariatric surgery results in increases in peptide YY which has an effect on satiety, and GLP-1, which affects gastric motility and beta-cell mass.
